Home › NDC Lookup › RxCUI directory › RxCUI 310285

Felbamate 120 MG/ML Oral Suspension — RxCUI 310285

RxNorm drug concept · Semantic clinical drug
RxCUI 310285 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI310285
Official nameFelbamate 120 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asFELT 120 MG/ML Oral Suspension; felbamate 600 MG in 5 mL Oral Suspension; felbamate 600 MG per 5 ML Oral Suspension
FDA products mapped6
Package NDCs mapped10
Reported Medicaid activity (SDUD)11,413 prescriptions · 35 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Felbamate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats severe epilepsy when other medicines haven't worked well enough. It's used for partial seizures in adults and for Lennox-Gastaut syndrome in children. It isn't a first-ch...
  • You take it by mouth, as tablets or liquid, several times a day. Follow your prescriber's schedule exactly. Never stop it suddenly, because seizures could increase.
  • Common ones include poor appetite, nausea, vomiting, trouble sleeping, headache, dizziness and sleepiness. Tell your doctor if they bother you or don't go away.
  • Call for signs of infection, unusual bleeding or bruising, or unusual paleness. Also call for yellow skin or eyes, dark urine, a serious rash, or any mood changes or thoughts of se...
📖 Read our full Felbamate guide →

🕸️ Concept Web — How Felbamate 120 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Felbamate 120 MG/ML Oral Suspension RxCUI 310285

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Felbamate 24812
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Felbatol 224900
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Felbamate Oral Suspension 372144
    • Felbamate Oral Liquid Product 1163809
    • Felbamate Oral Product 1163810
    • Felbamate Oral Suspension [Felbatol] 365878
    • Felbatol Oral Liquid Product 1176001
    • Felbatol Oral Product 1176002
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Felbamate 120 MG/ML SCDC · 315923
  • Felbamate Oral Suspension SCDF · 372144
  • Felbamate Oral Liquid Product SCDG · 1163809
  • Felbamate Oral Product SCDG · 1163810

Brand-Name Concepts

  • Felbamate 120 MG/ML Oral Suspension [Felbatol] SBD · 209028
  • Felbamate 120 MG/ML [Felbatol] SBDC · 569663
  • Felbamate Oral Suspension [Felbatol] SBDF · 365878
  • Felbatol Oral Liquid Product SBDG · 1176001
  • Felbatol Oral Product SBDG · 1176002
  • Felbatol BN · 224900

📦 FDA Products & Package NDCs

6 products · 10 package NDCs
10 package NDCs map to RxCUI 310285 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00037-0430-01 100 TABLET in 1 BOTTLE, PLASTIC (0037-0430-01) Felbatol Viatris Specialty LLC 1993-07-29
00037-0431-01 100 TABLET in 1 BOTTLE, PLASTIC (0037-0431-01) Felbatol Viatris Specialty LLC 1993-07-29
16714-0775-01 237 mL in 1 BOTTLE (16714-775-01) Felbamate NORTHSTAR RX LLC 2018-04-10
16714-0775-02 473 mL in 1 BOTTLE (16714-775-02) Felbamate NORTHSTAR RX LLC 2018-04-10
51672-4172-01 237 mL in 1 BOTTLE (51672-4172-1) Felbamate Taro Pharmaceuticals U.S.A., Inc. 2017-06-16
51672-4172-09 473 mL in 1 BOTTLE (51672-4172-9) Felbamate Taro Pharmaceuticals U.S.A., Inc. 2017-06-16
65162-0686-88 237 mL in 1 BOTTLE (65162-686-88) Felbamate Amneal Pharmaceuticals LLC 2011-12-16
65162-0686-90 473 mL in 1 BOTTLE (65162-686-90) Felbamate Amneal Pharmaceuticals LLC 2011-12-16
70954-0051-10 237 mL in 1 BOTTLE (70954-051-10) Felbamate Novitium Pharma LLC 2022-07-15
70954-0051-20 473 mL in 1 BOTTLE (70954-051-20) Felbamate Novitium Pharma LLC 2022-07-15
Observed labelers: Amneal Pharmaceuticals LLC (2) · NORTHSTAR RX LLC (2) · Novitium Pharma LLC (2) · Taro Pharmaceuticals U.S.A., Inc. (2) · Viatris Specialty LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.